Want to see HK:3933 full AI Analyst Report?
3933 Stock Chart & Stats
HK$8.77
-HK$0.10(-1.10%)
At close: 4:00 PM EDT
HK$8.77
-HK$0.10(-1.10%)
Day’s Range― - ―
52-Week RangeHK$6.85 - HK$13.72
Previous CloseN/A
Volume4.20M
Average Volume (3M)4.48M
Market Cap
HK$14.46B
Enterprise ValueHK$10.04B
Total Cash (Recent Filing)HK$11.73B
Total Debt (Recent Filing)HK$5.95B
Price to Earnings (P/E)22.1
Beta0.89
Next Earnings
Mar 30, 2027EPS Estimate
0.23Next Dividend Ex-DateN/A
Dividend Yield4.14%
Share Statistics
EPS (TTM)0.28
Shares Outstanding1,970,276,500
10 Day Avg. Volume3,433,704
30 Day Avg. Volume4,476,919
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)1.13
Price to Sales (P/S)1.49
P/FCF Ratio22.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$12.65Price Target Upside44.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.47
Revenue Forecast (FY)HK$12.33B
Bulls Say, Bears Say
Bulls Say
Diversified Pharmaceutical ModelThe combination of finished medicines and APIs provides multiple revenue channels across the pharmaceutical value chain. Internal and external API demand can complement dosage-product sales, while a broad therapeutic portfolio may support resilience and ongoing commercial reach.
Conservative Balance SheetModerate leverage and steadily growing equity provide a relatively strong financial foundation for a pharmaceutical manufacturer. This balance-sheet capacity can support continued operations and investment while reducing the strain that high debt would place on future cash flows.
Healthy Gross Margin And Positive Cash FlowA healthy gross margin indicates that the company retains meaningful economics from its pharmaceutical products despite recent pressure. Positive operating cash flow also shows that the core business generates cash, providing an operating base for reinvestment and ongoing commitments.
Bears Say
Revenue ContractionThe shift from strong expansion through 2023 to flat revenue in 2024 and contraction in 2025 signals weaker demand or execution momentum. Sustained top-line pressure could reduce scale benefits, limit reinvestment capacity, and make recovery in earnings more difficult.
Margin And Return CompressionLower margins and materially weaker return on equity show that the company is converting revenue and shareholder capital into profit less efficiently than before. If this persists, earnings quality and the ability to compound returns may remain below prior levels.
Volatile Cash ConversionWeak and inconsistent conversion of accounting profit into free cash flow reduces the reliability of reported earnings as a funding source. Volatility can constrain internally financed investment, dividends, or debt reduction even while the company remains profitable.
The United Laboratories International Holdings News
3933 FAQ
What was The United Laboratories International Holdings Limited’s price range in the past 12 months?
The United Laboratories International Holdings Limited lowest stock price was HK$6.85 and its highest was HK$13.72 in the past 12 months.
What is The United Laboratories International Holdings Limited’s market cap?
The United Laboratories International Holdings Limited’s market cap is HK$14.46B.
When is The United Laboratories International Holdings Limited’s upcoming earnings report date?
The United Laboratories International Holdings Limited’s upcoming earnings report date is Mar 30, 2027 which is in 157 days.
How were The United Laboratories International Holdings Limited’s earnings last quarter?
The United Laboratories International Holdings Limited released its earnings results on Aug 31, 2026. The company reported HK$0.207 earnings per share for the quarter, beating the consensus estimate of HK$0.153 by HK$0.054.
Is The United Laboratories International Holdings Limited overvalued?
According to Wall Street analysts The United Laboratories International Holdings Limited’s price is currently Undervalued.
Does The United Laboratories International Holdings Limited pay dividends?
The United Laboratories International Holdings Limited pays a Annually dividend of HK$0.299 which represents an annual dividend yield of 4.14%. See more information on The United Laboratories International Holdings Limited dividends here
What is The United Laboratories International Holdings Limited’s EPS estimate?
The United Laboratories International Holdings Limited’s EPS estimate is 0.23.
How many shares outstanding does The United Laboratories International Holdings Limited have?
The United Laboratories International Holdings Limited has 1,970,276,500 shares outstanding.
What happened to The United Laboratories International Holdings Limited’s price movement after its last earnings report?
The United Laboratories International Holdings Limited reported an EPS of HK$0.207 in its last earnings report, beating expectations of HK$0.153. Following the earnings report the stock price went down -3.398%.
Which hedge fund is a major shareholder of The United Laboratories International Holdings Limited?
Currently, no hedge funds are holding shares in HK:3933
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
The United Laboratories International Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.29%
12-Months-Change
Fundamentals
Return on Equity
3.12%
Trailing 12-Months
Asset Growth
15.21%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
The United Laboratories International Holdings Limited
The United Laboratories International Holdings Limited functions as an investment holding company with a primary focus on the pharmaceutical sector. Its multifaceted operations cover the entire lifecycle of drug development and commercialization, from pioneering research and development to manufacturing, distribution, and sales. The company structures its diverse business into three core divisions: Bulk Medicine, Intermediate Products, and Finished Goods. Its broad product portfolio features a variety of medications, such as oral antibiotics, injectable antimicrobials, cold and cough remedies, ophthalmic solutions, antiviral and anti-hepatitis B drugs, diabetes treatments, topical dermatological preparations, cardiovascular and neurological pharmaceuticals, vitamins, and empty gelatin capsules, alongside active pharmaceutical ingredients (APIs) and other intermediary compounds. Furthermore, the company manufactures and markets soft capsule shells, holds trademarks, engages in pharmaceutical trading, and provides management services. Founded in 1990 and headquartered in Yuen Long, Hong Kong, the firm maintains a significant global reach, conducting business throughout the People's Republic of China, Europe, India, the Middle East, South America, other Asian territories, and internationally.
3933 Stock 12 Month Forecast
Average Price Target
HK$12.65
▲(44.27% Upside)
Technical Analysis
China Medical System Holdings
―
Livzon Pharmaceutical Group
―
China Resources Pharmaceutical Group Ltd.
―
Consun Pharmaceutical Group Ltd.
―
Grand Pharmaceutical Group Limited
―